#United States #Bethesda #Precision for Medicine #Sofia Baig #Daisy DeWeese-Gatt

Precision for Medicine Appoints New Leadership

Precision for Medicine, part of the Precision Medicine Group, has revealed significant leadership changes aimed at boosting its growth in drug development services. Sofia Baig has been promoted to President of Precision for Medicine, while Daisy DeWeese-Gatt, MPH, assumes the role of President of Clinical Solutions. These appointments come at a time when the organization aims to enhance its capabilities in the pharma and biotechnology sectors.

Promoting Leadership Excellence

Sofia Baig previously held the position of President of Clinical Solutions, a role she took on in 2023. Baig is now positioned to oversee various services within Precision for Medicine, including Translational Sciences and Clinical Solutions. Her promotion replaces Chad Clark, who remains in his roles as President and COO of Precision Medicine Group.

Baig has dedicated nearly 15 years to expanding Precision for Medicine's reach and services. In her words, "It has been a privilege to contribute to the evolution of this organization and I look forward to leading our efforts in delivering innovative solutions that cater to the emerging needs of our clients, with a strong emphasis on patient-oriented drug development."

Chad Clark praised Baig’s contributions, noting, "Sofia's commitment and strategic vision have been crucial in positioning us as a leader in the clinical trials market, both in America and globally. I am excited to see how she will further harness our collective strengths to drive innovation and quality service."

New Addition with Global Insight

In tandem with Baig's elevation, Daisy DeWeese-Gatt joins the team as President of Clinical Solutions. DeWeese-Gatt comes with a wealth of experience—spanning over 25 years in clinical research with significant expertise in global drug development, particularly in oncology and rare diseases. Her background includes senior roles at notable organizations such as ICON and IQVIA.

"I am thrilled to join Precision for Medicine at such an exciting time in our industry," DeWeese-Gatt expressed. "I look forward to leveraging my experience to enhance our clinical operations and to help achieve our objectives of faster and more effective drug development."

Focus on Integration and Innovation

Precision for Medicine's mission is to focus on biomarker-driven research, which is vital for targeting more precise patient treatments. The organization delivers comprehensive drug development and commercialization services. By continuously integrating clinical trial design with robust scientific knowledge and data intelligence, they aim to expedite the approval process of new therapies.

This new leadership structure underscores Precision for Medicine's commitment to placing innovation at the forefront of its operations. With Baig and DeWeese-Gatt at the helm, the organization is poised to enhance its services, facilitating quicker access to groundbreaking therapeutic options for patients worldwide.

A Vision for the Future

As both leaders implement strategies and set targets for future growth, their combined expertise will be pivotal in ensuring that Precision for Medicine not only meets the challenges facing drug development today but also continues to lead the charge into the next generation of biomedical innovation. The focus will remain on creating a culture centered around people, innovation, and excellence in clinical solutions.

In summary, the appointments of Sofia Baig and Daisy DeWeese-Gatt mark a pivotal moment for Precision for Medicine, as they aim to strengthen their role as leaders in the healthcare landscape. This strategic expansion of leadership demonstrates their unwavering commitment to advancing drug development processes while maintaining the highest standards of quality and service delivery.